CHICAGO TRUST Co NA Acquires 953 Shares of IDEXX Laboratories, Inc. $IDXX

CHICAGO TRUST Co NA grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.9% during the second quarter, Holdings Channel reports. The institutional investor owned 3,686 shares of the company’s stock after acquiring an additional 953 shares during the quarter. CHICAGO TRUST Co NA’s holdings in IDEXX Laboratories were worth $1,977,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of IDXX. GAMMA Investing LLC boosted its holdings in shares of IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock valued at $3,856,950,000 after buying an additional 916,898 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after buying an additional 825,965 shares in the last quarter. Select Equity Group L.P. bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $194,834,000. Nuveen LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $179,784,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after buying an additional 414,802 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the sale, the executive vice president owned 6,156 shares of the company’s stock, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares in the company, valued at $11,034,299.71. This represents a 6.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock worth $34,293,468 in the last ninety days. Company insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IDXX shares. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. BTIG Research lifted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 4th. Finally, Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $649.44.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $644.10 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market cap of $51.53 billion, a price-to-earnings ratio of 53.63, a price-to-earnings-growth ratio of 4.25 and a beta of 1.56. The company has a 50 day moving average price of $616.70 and a 200-day moving average price of $523.10. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.